According to information from Jingxin Pharmaceutical, on October 8, Jingxin Pharmaceutical received a “Drug Registration Certificate” for “colevilene hydrochloride tablets” approved and issued by the State Drug Administration. This product is used to treat essential hyperlipidemia. It is the first in China to be approved for marketing, and is considered to have passed the consistent evaluation of the quality and efficacy of generic drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.